Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.45 |
| ▸ | KLK7 | P49862 | 6/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13248327 | 0.90 | KMT2A (0.48) | KMT2AL3MBTL1KLK5KLK7PDE4B | |
| SCHEMBL4755871 | 0.84 | KLK7 (0.50) | KMT2AL3MBTL1KLK5KLK7PDE4B | |
| SCHEMBL9774689 | 0.83 | CARM1 (0.44) | KMT2A | |
| SCHEMBL1360264 | 0.83 | PDE4B (0.56) | KMT2AL3MBTL1KLK5KLK7PDE4B | |
| SCHEMBL1360262 | 0.83 | PDE4B (0.56) | KMT2AL3MBTL1KLK5KLK7PDE4B | |
| SCHEMBL3388396 | 0.82 | PDE4B (0.54) | KMT2AL3MBTL1PDE4BSTSJAK2 | |
| SCHEMBL1355893 | 0.82 | PDE4B (0.54) | KMT2AL3MBTL1PDE4BSTSJAK2 | |
| SCHEMBL13315211 | 0.82 | PDE4B (0.54) | KMT2AL3MBTL1PDE4BSTSJAK2 | |
| SCHEMBL19918950 | 0.82 | PDE4B (0.54) | KMT2AL3MBTL1PDE4BSTSJAK2 | |
| SCHEMBL3388401 | 0.82 | PDE4B (0.54) | KMT2AL3MBTL1PDE4BSTSJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853586-B1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130150366-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA, INTELLECTUAL PROPERTY (GB) | 2013-06-13 | — | — | US | disclosed |
| US-8399489-B2 | Antibacterial piperdine derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20100179150-A1 | ANTIBACTERIAL PIPERDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150366-A1 | CHEMICAL COMPOUNDS | MRPL21, NISCH, CFTR | KMT2A 4273/4885L3MBTL1 3998/4885KLK5 974/4885 |
| US-20100179150-A1 | ANTIBACTERIAL PIPERDINE DERIVATIVES | PIR, HAMP, AMPD2 | KMT2A 3712/4885L3MBTL1 4649/4885KLK5 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.